Document Detail

Effect of food on the pharmacokinetics of (-) and (+) dOTC when administered as an oral racemate.
MedLine Citation:
PMID:  12043954     Owner:  NLM     Status:  MEDLINE    
The objective of this study was to evaluate the effect of food on the pharmacokinetics of racemic dOTC, a nucleoside analogue reverse transcriptase inhibitor, in adult male volunteers. Twelve healthy adult male subjects were enrolled in a randomized, open-label, single-dose crossover study. All were nonsmoking, within 15% of ideal body weight, and between 18 and 50 years of age. Subjects received single oral doses of 800mg racemic dOTC, in random order, either fed or fasted. The meal given to fed subjects was the standard Food and Drug Administration high-fat breakfast, and all subjects completed both study periods. Sixteen plasma samples for pharmacokinetic assessments were collected for 72 hours following dosing and assayed for (-) and (+) dOTC concentrations. Area under the plasma concentration-time curve (AUC), maximum observed plasma concentration (Cmax), and time to maximum concentration (tm) were determined for each enantiomer by standard noncompartmental techniques. Statistical hypothesis testing was by Wilcoxon signed rank, and the two one-sided tests procedure was used to determine bioequivalence between thefed and fasted study periods. The only effect of coadministration of racemic dOTC with food was a delay in time to peak concentration (t(max) of between 0.6 and 0.7 hours for both (-) and (+) dOTC stereoisomers (p < or =0.02). Neither AUC (p > or = 0.10) nor Cmax (p > or = 0.35) differed significantly between the fed and fasted study periods for either (-) or (+) dOTC. Both AUC and Cmax were equivalent between the fed and fasted study periods. It was concluded that there is no clinically significant effect of a high-fat meal on the pharmacokinetics of either (-) or (+) dOTC when administered orally as a racemic mixture.
Patrick F Smith; Alan Forrest; John M Adams; Charles H Ballow
Related Documents :
8280824 - An investigation into the effect of cimetidine pre-treatment on raft formation of an an...
9409274 - Effects of dietary fat quality and quantity on postprandial activation of blood coagula...
9022534 - Splanchnic and whole-body leucine kinetics in young and elderly men.
3790084 - The content of pentose-cycle intermediates in liver in starved, fed ad libitum and meal...
1527644 - Changes in serum and lipoprotein fatty acids of growing rats fed protein-deficient diet...
21742944 - Effects of vitamin e on color stability and palatability of strip loin steaks from catt...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of clinical pharmacology     Volume:  42     ISSN:  0091-2700     ISO Abbreviation:  J Clin Pharmacol     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-06-04     Completed Date:  2002-11-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0366372     Medline TA:  J Clin Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  658-61     Citation Subset:  IM    
University at Buffalo School of Pharmacy and Pharmaceutical Sciences, New York 14260, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Area Under Curve
Cross-Over Studies
Deoxycytidine / administration & dosage,  analogs & derivatives*,  pharmacokinetics*
Middle Aged
Reverse Transcriptase Inhibitors / pharmacokinetics*
Thionucleosides / administration & dosage,  pharmacokinetics*
Reg. No./Substance:
0/2'-deoxy-3'-oxa-thiocytidine; 0/Reverse Transcriptase Inhibitors; 0/Thionucleosides; 951-77-9/Deoxycytidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-rel...
Next Document:  A new solution-based intranasal triamcinolone acetonide formulation in patients with perennial aller...